154 related articles for article (PubMed ID: 2573056)
21. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results.
Gotthardt M; Fischer M; Naeher I; Holz JB; Jungclas H; Fritsch HW; Béhé M; Göke B; Joseph K; Behr TM
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):597-606. PubMed ID: 11976797
[TBL] [Abstract][Full Text] [Related]
22. Dexamethasone pretreatment of rat insulinoma cells decreases binding of glucagon-like peptide-1(7-36)amide.
Richter G; Göke R; Göke B; Arnold R
J Endocrinol; 1990 Sep; 126(3):445-50. PubMed ID: 2170555
[TBL] [Abstract][Full Text] [Related]
23. Stimulatory effects of glucagon-like peptides on human insulinoma cells and insulin-releasing clonal RINm5F cells.
Flatt PR; Shiber O; Hampton SM; Marks V
Diabetes Res; 1990 Feb; 13(2):55-9. PubMed ID: 1965428
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas.
Suzuki S; Kawai K; Ohashi S; Mukai H; Yamashita K
Endocrinology; 1989 Dec; 125(6):3109-14. PubMed ID: 2684616
[TBL] [Abstract][Full Text] [Related]
25. Glucagon-like peptide-1(7-36)amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes.
Miki H; Namba M; Nishimura T; Mineo I; Matsumura T; Miyagawa J; Nakajima H; Kuwajima M; Hanafusa T; Matsuzawa Y
Biochim Biophys Acta; 1996 Jun; 1312(2):132-6. PubMed ID: 8672535
[TBL] [Abstract][Full Text] [Related]
26. Amylin alters the biological action of the incretin hormone GLP-1(7-36)amide.
Göke R; McGregor GP; Göke B
Life Sci; 1993; 53(17):1367-72. PubMed ID: 7692203
[TBL] [Abstract][Full Text] [Related]
27. Glucagonlike peptide-1(7-36)amide suppresses glucagon secretion and decreases cyclic AMP concentration in cultured In-R1-G9 cells.
Matsumura T; Itoh H; Watanabe N; Oda Y; Tanaka M; Namba M; Kono N; Matsuyama T; Komatsu R; Matsuzawa Y
Biochem Biophys Res Commun; 1992 Jul; 186(1):503-8. PubMed ID: 1378730
[TBL] [Abstract][Full Text] [Related]
28. [The entero-insular axis: the new incretin candidate glucagon-like peptide-1(7-36)amide (GLP-1(7-36))amide].
Göke R; Göke B; Richter G; Arnold R
Z Gastroenterol; 1988 Nov; 26(11):715-9. PubMed ID: 2849249
[TBL] [Abstract][Full Text] [Related]
29. N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity.
John H; Maronde E; Forssmann WG; Meyer M; Adermann K
Eur J Med Res; 2008 Feb; 13(2):73-8. PubMed ID: 18424366
[TBL] [Abstract][Full Text] [Related]
30. Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors.
Gromada J; Ding WG; Barg S; Renström E; Rorsman P
Pflugers Arch; 1997 Sep; 434(5):515-24. PubMed ID: 9242714
[TBL] [Abstract][Full Text] [Related]
31. Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors.
Moens K; Flamez D; Van Schravendijk C; Ling Z; Pipeleers D; Schuit F
Diabetes; 1998 Jan; 47(1):66-72. PubMed ID: 9421376
[TBL] [Abstract][Full Text] [Related]
32. Neuropeptide Y expression and regulation in a differentiated rat insulin-secreting cell line.
Waeber G; Thompson N; Waeber B; Brunner HR; Nicod P; Grouzmann E
Endocrinology; 1993 Sep; 133(3):1061-7. PubMed ID: 8396008
[TBL] [Abstract][Full Text] [Related]
33. Glucagon-like peptide-1-(7-36)amide and a rise in cyclic adenosine 3',5'-monophosphate increase cytosolic free Ca2+ in rat pancreatic beta-cells by enhancing Ca2+ channel activity.
Yada T; Itoh K; Nakata M
Endocrinology; 1993 Oct; 133(4):1685-92. PubMed ID: 8404610
[TBL] [Abstract][Full Text] [Related]
34. Reduced insulinotropic effects of glucagonlike peptide I-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas.
Suzuki S; Kawai K; Ohashi S; Mukai H; Murayama Y; Yamashita K
Diabetes; 1990 Nov; 39(11):1320-5. PubMed ID: 2146178
[TBL] [Abstract][Full Text] [Related]
35. Comparison of GLP-1 (7-36amide) and GIP on release of somatostatin-like immunoreactivity and insulin from the isolated rat pancreas.
Schmid R; Schusdziarra V; Aulehner R; Weigert N; Classen M
Z Gastroenterol; 1990 Jun; 28(6):280-4. PubMed ID: 2238756
[TBL] [Abstract][Full Text] [Related]
36. Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide.
Eissele R; Bothe-Sandfort E; Göke B; Eng J; Arnold R; Koop H
Life Sci; 1994; 55(8):629-34. PubMed ID: 7913983
[TBL] [Abstract][Full Text] [Related]
37. Effects of glucagon-like peptide-1 (GLP-1) in RINm5F insulinoma cells. Stimulation of insulin secretion, insulin content, and insulin receptor binding.
Jehle PM; Jehle D; Fussgänger RD; Adler G
Exp Clin Endocrinol Diabetes; 1995; 103 Suppl 2():31-6. PubMed ID: 8839251
[TBL] [Abstract][Full Text] [Related]
38. Carbachol priming increases glucose- and glucagon-like peptide-1 (7-36)amide-, but not arginine-induced insulin secretion from the isolated perfused rat pancreas.
Fehmann HC; Göke R; Göke B; Arnold R
Z Gastroenterol; 1990 Jul; 28(7):348-52. PubMed ID: 2238765
[TBL] [Abstract][Full Text] [Related]
39. Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat.
Eissele R; Koop H; Arnold R
Scand J Gastroenterol; 1990 May; 25(5):449-54. PubMed ID: 1972810
[TBL] [Abstract][Full Text] [Related]
40. Characterization of binding sites for oxyntomodulin on a somatostatin-secreting cell line (RIN T3).
Gros L; Demirpence E; Jarrousse C; Kervran A; Bataille D
Endocrinology; 1992 Mar; 130(3):1263-70. PubMed ID: 1371446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
